H.C. Wainwright raised its price target for Aravive (NASDAQ:ARAV) to $12 from $7 after increasing its probability of success for batiraxcept to 55% from 35% for platinum-resistant ovarian cancer (PROC) “to further value...
H.C. Wainwright launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and a price target of $11. The stock closed at $3.88 on Feb. 10. At its core, OmniAb is an antibody discovery, optimization, and licensing...
H.C. Wainwright upgraded BerGenBio (OSLO:BGBIO) to “buy” from “neutral” with a price target of NOK30. The stock closed at NOK6.70 on Nov. 25. “As 2022 is coming to a close, we believe now is an opportune time to step...
H.C.Wainwright initiated coverage of Clene (NASDAQ:CLNN) with a “buy” rating and price target of $16. The stock closed at $4.50 on July 15. Clene is focused on the development of novel clean-surfaced nanotechnologies...
H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...
Analysts for H.C. Wainwright and Cantor Fitzgerald raised their price targets for Checkpoint Therapeutics (NASDAQ:CKPT) to $26 and $20, respectively, after the company reported positive pivotal data with anti-PD-L1...
H.C. Wainwright initiated coverage of Biophytis SA of France (NASDAQ:BPTS) with a “buy” rating and $15 price target. The stock closed at $6.09 on Oct. 22. As a spin-off from Sorbonne University in 2006, Biophytis has...
H.C. Wainwright launched coverage of Progenity (NASDAQ:PROG) with a “buy” rating and price target of $4. The stock closed at $2.04 on Oct. 13. Progenity’s differentiated R&D pipeline primarily focuses on employing...
H.C. Wainwright upgraded BeyondSpring (NASDAQ:BYSI) to “buy” from “neutral” with a price target of $100 after the company reported positive topline results from its DUBLIN-3 registrational trial of plinabulin in...
H.C. Wainwright raised its price target for PDS Biotechnology (NASDAQ:PDSB) to $20 from $8 ahead of additional data being released at the ASCO meeting this weekend. The stock closed at $10.86 on June 1. “We believe that...